---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343434"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-08-11T11:20:34+00:00"
generated_at: "2026-08-11T11:25:08.854701+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tango Q2 net loss $55.3M; vopimetostat combo 92% ORR, cash $1B

## Summary
- Q2 net loss $55.3M ($0.37/share) vs $38.9M ($0.35/share) YoY; cash $1.0B as of June 30, 2026.
- Vopimetostat + daraxonrasib showed 92% ORR and 90% 6-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer; advancing to Phase 3.
- Data to be presented at ESMO 2026 (Oct 23-27, Madrid); plans to finalize Phase 3 design in 2H 2026.
- Fatma Ocak appointed Chief Commercialization Officer effective Aug 17, 2026; Robert Azelby named Chairman Aug 6, 2026.
- R&D expenses $37.2M (up from $32.8M), G&A $22.6M (up from $11.3M); collaboration revenue $0 vs $3.2M.

## SEC filing metadata
- accession: 0001193125-26-343434
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-08-11T11:20:34+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/0001193125-26-343434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/tngx-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343434
- JSON: https://secwatch.observer/filing/0001193125-26-343434.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343434.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.